Cytokinetics Inc financial data

Symbol
CYTK on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Oyster Point Boulevard, ., South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 778 % -20.2%
Debt-to-equity -450 % +30.5%
Return On Equity 196 % -37.7%
Return On Assets -56 % +2.49%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 118M shares +22.6%
Common Stock, Shares, Outstanding 102M shares +7.18%
Entity Public Float 2B USD 0%
Common Stock, Value, Issued 117K USD +24.5%
Weighted Average Number of Shares Outstanding, Basic 109K shares +14.1%
Weighted Average Number of Shares Outstanding, Diluted 109K shares +14.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.13M USD -68.5%
Research and Development Expense 329M USD +9.42%
General and Administrative Expense 181M USD -5.76%
Operating Income (Loss) -506M USD -5%
Nonoperating Income (Expense) 33.9M USD +45.7%
Net Income (Loss) Attributable to Parent -545M USD -1.05%
Earnings Per Share, Basic -5.37 USD/shares +6.93%
Earnings Per Share, Diluted -5.37 USD/shares +6.93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 190M USD +177%
Cash, Cash Equivalents, and Short-term Investments 1.4B USD +136%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 1.07B USD +82%
Property, Plant and Equipment, Net 65.7M USD -15%
Operating Lease, Right-of-Use Asset 77.2M USD -4.47%
Other Assets, Noncurrent 7.68M USD -7.92%
Assets 1.52B USD +95.4%
Accounts Payable, Current 9.47M USD -24.6%
Employee-related Liabilities, Current 20M USD +20.4%
Accrued Liabilities, Current 39.8M USD +26.5%
Liabilities, Current 103M USD +56.6%
Operating Lease, Liability, Noncurrent 117M USD -5.74%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 1.42B USD +27.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.02M USD +29.9%
Retained Earnings (Accumulated Deficit) -2.39B USD -29.5%
Stockholders' Equity Attributable to Parent 109M USD
Liabilities and Equity 1.52B USD +95.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -130M USD -5.91%
Net Cash Provided by (Used in) Financing Activities 104M USD
Net Cash Provided by (Used in) Investing Activities 32.6M USD -80.3%
Common Stock, Shares Authorized 163M shares 0%
Common Stock, Shares, Issued 102M shares +7.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.95M USD -80.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 113M USD +68.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 10.2M USD +25415%
Deferred Tax Assets, Valuation Allowance 573M USD +29%
Deferred Tax Assets, Gross 597M USD +27%
Operating Lease, Liability 138M USD -1.01%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -545M USD -1.54%
Lessee, Operating Lease, Liability, to be Paid 210M USD -6.03%
Property, Plant and Equipment, Gross 97.1M USD -0.46%
Operating Lease, Liability, Current 18.5M USD +17.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 19.6M USD +4.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 18.7M USD +39.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 71.4M USD -14.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.2M USD +3.15%
Deferred Tax Assets, Operating Loss Carryforwards 232M USD +14.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 25.2M USD +37.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.5M USD +1.66%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.33M USD +26.1%
Share-based Payment Arrangement, Expense 84.4M USD +39.5%
Interest Expense 34.1M USD +22.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%